Search

Your search keyword '"Distefano, Mariagrazia"' showing total 137 results
Start Over Author "Distefano, Mariagrazia"
137 results on '"Distefano, Mariagrazia"'

2. Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial

Author

Di Liello, Raimondo, Arenare, Laura, Raspagliesi, Francesco, Scambia, Giovanni, Pisano, Carmela, Colombo, Nicoletta, Frezzini, Simona, Tognon, Germana, Artioli, Grazia, Gadducci, Angiolo, Lauria, Rossella, Ferrero, Annamaria, Cinieri, Saverio, De Censi, Andrea, Breda, Enrico, Scollo, Paolo, De Giorgi, Ugo, Lissoni, Andrea Alberto, Katsaros, Dionyssios, Lorusso, Domenica, Salutari, Vanda, Cecere, Sabrina Chiara, Lapresa, Mariateresa, Nardin, Margherita, Bogani, Giorgio, Distefano, Mariagrazia, Greggi, Stefano, Gargiulo, Piera, Schettino, Clorinda, Gallo, Ciro, Daniele, Gennaro, Califano, Daniela, Perrone, Francesco, Pignata, Sandro, and Piccirillo, Maria Carmela

Published
2021
Full Text
View/download PDF

5. #709 The effects of niraparib dose reduction on long-term outcomes in ovarian cancer patients: a large retrospective, observational study

Author

Apostol, Adriana Ionelia, primary, Sassu, Carolina Maria, additional, Lardino, Sara, additional, Boccia, Serena Maria, additional, Corrado, Giacomo, additional, Palluzzi, Eleonora, additional, Distefano, Mariagrazia, additional, Lorusso, Domenica, additional, Scambia, Giovanni, additional, Fagotti, Anna, additional, and Marchetti, Claudia, additional

Published
2023
Full Text
View/download PDF

7. A common pattern of somatic mutations in t‐MDS / AML of patients treated with PARP inhibitors for metastatic ovarian cancer

Author

Chiusolo, Patrizia, primary, Marchetti, Claudia, additional, Rossi, Monica, additional, Minnella, Gessica, additional, Salutari, Vanda, additional, Distefano, Mariagrazia, additional, Giammarco, Sabrina, additional, Metafuni, Elisabetta, additional, Minucci, Angelo, additional, Frioni, Filippo, additional, Gasbarrino, Cristiana, additional, Colangelo, Maria, additional, Orteschi, Daniela, additional, Fagotti, Anna, additional, Lorusso, Domenica, additional, Pagano, Livio, additional, De Stefano, Valerio, additional, Scambia, Giovanni, additional, and Sica, Simona, additional

Published
2022
Full Text
View/download PDF

9. A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer

Author

Chiusolo, Patrizia, Marchetti, Claudia, Rossi, Monica, Minnella, Gessica, Salutari, Vanda, Distefano, Mariagrazia, Giammarco, Sabrina, Metafuni, Elisabetta, Minucci, Angelo, Frioni, Filippo, Gasbarrino, Cristiana, Colangelo, Maria, Orteschi, Daniela, Fagotti, Anna, Lorusso, Domenica, Pagano, Livio, De Stefano, Valerio, Scambia, Giovanni, Sica, Simona, Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Marchetti, Claudia (ORCID:0000-0001-7098-8956), Fagotti, Anna (ORCID:0000-0001-5579-335X), Pagano, Livio (ORCID:0000-0001-8287-928X), De Stefano, Valerio (ORCID:0000-0002-5178-5827), Scambia, Giovanni (ORCID:0000-0003-2758-1063), Sica, Simona (ORCID:0000-0003-2426-3465), Chiusolo, Patrizia, Marchetti, Claudia, Rossi, Monica, Minnella, Gessica, Salutari, Vanda, Distefano, Mariagrazia, Giammarco, Sabrina, Metafuni, Elisabetta, Minucci, Angelo, Frioni, Filippo, Gasbarrino, Cristiana, Colangelo, Maria, Orteschi, Daniela, Fagotti, Anna, Lorusso, Domenica, Pagano, Livio, De Stefano, Valerio, Scambia, Giovanni, Sica, Simona, Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Marchetti, Claudia (ORCID:0000-0001-7098-8956), Fagotti, Anna (ORCID:0000-0001-5579-335X), Pagano, Livio (ORCID:0000-0001-8287-928X), De Stefano, Valerio (ORCID:0000-0002-5178-5827), Scambia, Giovanni (ORCID:0000-0003-2758-1063), and Sica, Simona (ORCID:0000-0003-2426-3465)

Abstract

inglese

Published
2022

10. Secondary malposition of a PICC-port due to heavy physical exercise: A case report

Author

D’Arrigo, Sonia, Annetta, Maria Giuseppina, Musarò, Andrea, Distefano, Mariagrazia, and Pittiruti, Mauro

Abstract

Physical exercise is often encouraged in cancer patients, mainly for the purpose of rehabilitation and for its psychological benefit. Some authors also suggest that exercise—specially in patient with peripherally inserted central venous access devices—may contribute to reduce the risk of catheter-related thrombosis. Still, the impact of physical exercise on the risk of device-related complications is not yet defined.We report a case of secondary migration of the tip of an arm port, caused by high-intensity exercise in a woman undergoing chemotherapy because of ovarian cancer. Tip migration was suspected because of malfunction (persistent withdrawal occlusion) and diagnosis established after ultrasound examination and chest x-ray.Even if exercise may yield benefit in the cancer patient on chemotherapy, the risk of mechanical complication of the venous access device—such as tip migration—should be considered in the case of high-intensity exercise.

Published
2023
Full Text
View/download PDF

15. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study

Author

Daniele, Gennaro, primary, Raspagliesi, Francesco, additional, Scambia, Giovanni, additional, Pisano, Carmela, additional, Colombo, Nicoletta, additional, Frezzini, Simona, additional, Tognon, Germana, additional, Artioli, Grazia, additional, Gadducci, Angiolo, additional, Lauria, Rossella, additional, Ferrero, Annamaria, additional, Cinieri, Saverio, additional, De Censi, Andrea, additional, Breda, Enrico, additional, Scollo, Paolo, additional, De Giorgi, Ugo, additional, Lissoni, Andrea Alberto, additional, Katsaros, Dionyssios, additional, Lorusso, Domenica, additional, Salutari, Vanda, additional, Cecere, Sabrina Chiara, additional, Zaccarelli, Eleonora, additional, Nardin, Margherita, additional, Bogani, Giorgio, additional, Distefano, Mariagrazia, additional, Greggi, Stefano, additional, Piccirillo, Maria Carmela, additional, Fossati, Roldano, additional, Giannone, Gaia, additional, Arenare, Laura, additional, Gallo, Ciro, additional, Perrone, Francesco, additional, and Pignata, Sandro, additional

Published
2021
Full Text
View/download PDF

23. New medical approaches in advanced ovarian cancer

Author

Corrado, Giacomo, primary, Palluzzi, Eleonora, additional, Bottoni, Carolina, additional, Pietragalla, Antonella, additional, Salutari, Vanda, additional, Ghizzoni, Viola, additional, Distefano, Mariagrazia, additional, Scambia, Giovanni, additional, and Ferrandina, Gabriella, additional

Published
2019
Full Text
View/download PDF

26. New medical approaches in advanced ovarian cancer

Author

Corrado, Giacomo, Palluzzi, Eleonora, Bottoni, Carolina, Pietragalla, Antonella, Salutari, Vanda, Ghizzoni, Viola, Distefano, Mariagrazia, Scambia, Giovanni, Ferrandina, Maria Gabriella, Scambia, Giovanni (ORCID:0000-0003-2758-1063), Ferrandina, Gabriella (ORCID:0000-0003-4672-4197), Corrado, Giacomo, Palluzzi, Eleonora, Bottoni, Carolina, Pietragalla, Antonella, Salutari, Vanda, Ghizzoni, Viola, Distefano, Mariagrazia, Scambia, Giovanni, Ferrandina, Maria Gabriella, Scambia, Giovanni (ORCID:0000-0003-2758-1063), and Ferrandina, Gabriella (ORCID:0000-0003-4672-4197)

Abstract

Ovarian cancer is the fifth leading cause of cancer death among women and the most lethal gynaecologic malignancy. Most women with advanced epithelial ovarian cancer will experience many episodes of recurrent disease with progressively shorter disease-free intervals. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Enormous progress has been made in the management of this disease, and new targeted treatments such as antiangiogenic drugs, poly(adenosine diphosphate-ribose) polymerase inhibitors, and immune checkpoint inhibitors offer potential for improved survival. A variety of combination strategies are being evaluated to leverage these agents. The objective of this review is to summarize results from clinical trials that tested cytotoxic drugs and target strategies for the treatment of ovarian cancer with particular attention to Phase III and ongoing trials.

Published
2019

29. Could lymphadenectomy be avoided in locally advanced cervical cancer patients administered preoperative chemoradiation? A large-scale retrospective study

Author

Ferrandina, Gabriella, primary, Distefano, Mariagrazia, additional, Mascilini, Floriana, additional, Gallotta, Valerio, additional, Chiantera, Vito, additional, Cosentino, Francesco, additional, Costantini, Barbara, additional, Ercoli, Alfredo, additional, Pedone Anchora, Luigi, additional, Fanfani, Francesco, additional, Margariti, Alessandro Pasquale, additional, Valentini, Vincenzo, additional, and Scambia, Giovanni, additional

Published
2017
Full Text
View/download PDF

31. Could lymphadenectomy be avoided in locally advanced cervical cancer patients administered preoperative chemoradiation? A large-scale retrospective study

Author

Ferrandina, Maria Gabriella, Distefano, Mariagrazia, Mascilini, Floriana, Gallotta, Valerio, Chiantera, Vito, Cosentino, Francesco, Costantini, Barbara, Ercoli, Alfredo, Pedone Anchora, Luigi, Fanfani, Francesco, Margariti, Alessandro Pasquale, Valentini, Vincenzo, Scambia, Giovanni, Ferrandina, Gabriella (ORCID:0000-0003-4672-4197), Fanfani, Francesco (ORCID:0000-0002-4354-5735), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Scambia, Giovanni (ORCID:0000-0003-2758-1063), Ferrandina, Maria Gabriella, Distefano, Mariagrazia, Mascilini, Floriana, Gallotta, Valerio, Chiantera, Vito, Cosentino, Francesco, Costantini, Barbara, Ercoli, Alfredo, Pedone Anchora, Luigi, Fanfani, Francesco, Margariti, Alessandro Pasquale, Valentini, Vincenzo, Scambia, Giovanni, Ferrandina, Gabriella (ORCID:0000-0003-4672-4197), Fanfani, Francesco (ORCID:0000-0002-4354-5735), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), and Scambia, Giovanni (ORCID:0000-0003-2758-1063)

Abstract

Introduction To identify a subset of cervical cancer (CC) patients administered chemoradiation (CT/RT) plus radical surgery (RS), who can be spared lymphadenectomy, and complications. Patients and methods 430 Stage IB2-IIB patients without LN involvement at imaging were accrued (March 1996–December 2015) at Gynecologic Oncology Unit of the Catholic University of Rome/Campobasso. CT/RT consisted of pelvic irradiation plus cisplatin based chemotherapy. Objective response was evaluated according to RECIST criteria; radical hysterectomy and pelvic ± aortic lymphadenectomy was attempted in patients achieving response or stable disease. Surgical morbidity was classified according to the Chassagne grading system. Results 421 cases underwent RS; metastatic pelvic and aortic LNs were documented in 10.7%, and 8.8% of cases, respectively. In patients without residual tumor in the cervix, there was only 1 case (0.53%) with positive pelvic LNs, and 1 case (2.3%) with metastatic aortic LNs. Analysis of patients according to pre- and post-CT/RT imaging was able to select cases without any metastatic LNs: in patients with negative pelvic LNs at pre- and post-CT/RT imaging, none of cases without residual disease in the cervix had metastatic pelvic or aortic LNs. Of 149 early complications, 76 (51.0%) were lymphovascular. The most frequent late complications were lymphovascular (N = 25/61, 41.0%). Conclusion Lymphadenectomy could be avoided in stage IB2-IIB CC patients undergoing preoperative CT/RT, when a careful evaluation of pre- and post-CT/RT imaging and histological assessment of no residual disease in the cervix is made. This approach may avoid lymphadenectomy in 40% of patients with a favourable impact on lymphovascular morbidity.

Published
2017

32. Real-world management of trabectedin/pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian cancer patients: A national survey

Author

Ferrandina, Maria Gabriella, Amadio, Giulia, Paris, Ida, Distefano, Mariagrazia, Palluzzi, Eleonora, De Vincenzo, Rosa Pasqualina, Ricci, Caterina, Scambia, Giovanni, Ferrandina, Gabriella (ORCID:0000-0003-4672-4197), De Vincenzo, Rosa (ORCID:0000-0001-7408-0435), Scambia, Giovanni (ORCID:0000-0003-2758-1063), Ferrandina, Maria Gabriella, Amadio, Giulia, Paris, Ida, Distefano, Mariagrazia, Palluzzi, Eleonora, De Vincenzo, Rosa Pasqualina, Ricci, Caterina, Scambia, Giovanni, Ferrandina, Gabriella (ORCID:0000-0003-4672-4197), De Vincenzo, Rosa (ORCID:0000-0001-7408-0435), and Scambia, Giovanni (ORCID:0000-0003-2758-1063)

Abstract

Background Trabectedin (T) plus pegylated liposomal doxorubicin (PLD) is approved for treatment of platinum-sensitive recurrent ovarian cancer (ROC). Despite the recommendations and guidelines, variations in managing T/PLD administration in routine clinical practice cannot be excluded. We aimed at setting up an Italian survey collecting data about management of T/PLD administration in ROC patients. Methods We carried out the development of a questionnaire-based survey on routine clinical practice in the management of ROC patients administered T/PLD. The survey registered the physicians' approach to modification/discontinuation of treatment, type of modifications, reasons why, and so on. The survey was transmitted to medical oncologists and gynecologic oncologists practicing in national centers/institutions. Results Fifty-eight Italian centers/institutions returned the compiled questionnaire; participants practiced at community cancer centers or hospitals (56.9%), academic institutions (36.2%), and other settings (private clinics, etc) (6.9%). There was no statistically significant difference in the distribution of practice setting according to geographic areas. Most responders were medical oncologists (84.5%) and were members (82.8%) of at least 1 scientific society or cooperative group. Almost 31.5% of responders reported interruption of the whole treatment, mostly because of toxicity (41.2%), followed by patients' choice (29.4%), or achievement of clinical benefit (23.5%). Dose reduction was referred by 47.4% of responders. Reduction of dose for both drugs was referred by 88.5% of responders, and the extent of dose reduction ranged between 10% and 30%. Conclusions This survey highlights the gaps in transposing evidence-based or consensus guidelines in the real-world management of T/PLD administration; these findings could be useful in order to focus the attention on specific knowledge and/or experience gaps and plan pertinent educational programs.

Published
2017

33. Preoperative chemoradiotherapy in locally advanced cervical cancer: long-term outcome and complications

Author

Fanfani Francesco, Fagotti Anna, Ferrandina Maria Gabriella, Scambia Giovanni, Smaniotto Daniela, D'Agostino Giuseppe, Morganti Alessio, and Distefano Mariagrazia

Subjects
Adult, medicine.medical_specialty, medicine.medical_treatment, Uterine Cervical Neoplasms, Hysterectomy, Preoperative care, Disease-Free Survival, Preoperative Care, Carcinoma, medicine, Humans, Radical surgery, Pathological, Pelvis, Aged, Neoplasm Staging, Cervical cancer, Cisplatin, business.industry, Obstetrics and Gynecology, Middle Aged, medicine.disease, Neoadjuvant Therapy, Surgery, Radiation therapy, Radiography, medicine.anatomical_structure, Treatment Outcome, Oncology, Carcinoma, Squamous Cell, Lymph Node Excision, Female, business, medicine.drug, Follow-Up Studies
Abstract

Objective. To demonstrate the efficacy and feasibility of preoperative chemoradiotherapy in a consecutive series of 100 locally advanced cervical cancer (LACC) patients. Methods. Between October 1997 and December 2004, 100 LACC patients were consecutively staged and treated at the Catholic University of the Sacred Heart of Rome. Radiotherapy was administered to the whole pelvic region (1.8 Gy/day, totaling 39.6 Gy) in combination with cisplatin (20 mg/m 2 ) and 5-FU (1000 mg/m 2 ) (both on days 1–4 and 27–30). Radical surgery was performed 5–6 weeks after the end of the treatment. Results. A clinical complete or partial response was observed in 96 patients (56 and 40, respectively). Radical surgery was performed in 95 patients and an overall complication rate of 12.6% was observed in the early postoperative time. At pathological examination, 43 of 95 patients (45.2%) undergoing radical surgery showed complete response to treatment, 28 patients (29.5%) only had a microscopic disease, 18 patients (19%) had a partial response and 6 (6.3%) had no change of disease. With a median follow-up time of 25 months, the 5-year disease-free survival was 76% and the 5-year overall survival was 78%. Conclusions. These data confirm the possibility of achieving encouraging rates of local control and OS in LACC patients submitted to chemoradiation plus surgery, with a low rate of toxicity and complications.

Published
2005

34. Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study

Author

Ferrandina, Gabriella, primary, Corrado, Giacomo, additional, Mascilini, Floriana, additional, Malaguti, Paola, additional, Samaritani, Riccardo, additional, Distefano, Mariagrazia, additional, Masciullo, Valeria, additional, Di Legge, Alessia, additional, Savarese, Antonella, additional, and Scambia, Giovanni, additional

Published
2014
Full Text
View/download PDF

39. Concomitant Radiochemotherapy plus Surgery in Locally Advanced Cervical Cancer: Update of Clinical Outcome and Cyclooxygenase-2 as Predictor of Treatment Susceptibility

Author

Distefano, Mariagrazia, primary, Ferrandina, Gabriella, additional, Smaniotto, Daniela, additional, Margariti, Alessandro Pasquale, additional, Zannoni, Gianfranco, additional, Macchia, Gabriella, additional, Manfredi, Riccardo, additional, Mangiacotti, Maria Grazia, additional, Cellini, Numa, additional, and Scambia, Giovanni, additional

Published
2004
Full Text
View/download PDF

40. Bcl-2 Down-Regulation Is a Novel Mechanism of Paclitaxel Resistance

Author

Ferlini, Cristiano, primary, Raspaglio, Giuseppina, additional, Mozzetti, Simona, additional, Distefano, Mariagrazia, additional, Filippetti, Flavia, additional, Martinelli, Enrica, additional, Ferrandina, Gabriella, additional, Gallo, Daniela, additional, Ranelletti, Franco Oreste, additional, and Scambia, Giovanni, additional

Published
2003
Full Text
View/download PDF

44. Anti-proliferative activity of a new class of taxanes (14β-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells

Author

Distefano, Mariagrazia, primary, Scambia, Giovanni, additional, Ferlini, Cristiano, additional, Gaggini, Cristiana, additional, Vincenzo, Rosa De, additional, Riva, Antonella, additional, Bombardelli, Ezio, additional, Ojima, Iwao, additional, Fattorossi, Andrea, additional, Panici, Pierluigi Benedetti, additional, and Mancuso, Salvatore, additional

Published
1997
Full Text
View/download PDF

47. Expression of ras p21 Oncoprotein in Normal and Neoplastic Human Endometrium

Author

Scambia, Giovanni, primary, Catozzi, Laura, additional, Benedetti-Panici, Pierluigi, additional, Ferrandina, Gabriella, additional, Battaglia, Francesco, additional, Giovannini, Gloria, additional, Distefano, Mariagrazia, additional, Pellizzola, Dario, additional, Piffanelli, Adriano, additional, and Mancuso, Salvatore, additional

Published
1993
Full Text
View/download PDF

49. EGF receptor expression in primary laryngeal cancer: Correlation with clinico-pathological features and prognostic significance

Author

Maurizi, Maurizio, primary, Scambia, Giovanni, additional, Panici, Pierluigi Benedetti, additional, Ferrandina, Gabriella, additional, Almadori, Giovanni, additional, Paludetti, Gaetano, additional, De Vincenzo, Rosa, additional, Distefano, Mariagrazia, additional, Brinchi, Domenico, additional, Cadoni, Gabriella, additional, and Mancuso, Salvatore, additional

Published
1992
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results